Identifying biomarkers for diagnosis and disease activity monitoring in PSC-IBD and UC through proteomic profiling: A prospective, biomarker discovery single-center study protocol
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064190%3A_____%2F26%3A10001455" target="_blank" >RIV/00064190:_____/26:10001455 - isvavai.cz</a>
Result on the web
<a href="https://doi.org/10.1371/journal.pone.0341885" target="_blank" >https://doi.org/10.1371/journal.pone.0341885</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1371/journal.pone.0341885" target="_blank" >10.1371/journal.pone.0341885</a>
Alternative languages
Result language
angličtina
Original language name
Identifying biomarkers for diagnosis and disease activity monitoring in PSC-IBD and UC through proteomic profiling: A prospective, biomarker discovery single-center study protocol
Original language description
Inflammatory bowel diseases (IBD) and primary sclerosing cholangitis (PSC) are chronic inflammatory conditions with limited biomarker-driven diagnostic tools. Proteomic profiling offers a promising approach to uncover specific biomarkers that could refine diagnostic accuracy, monitor disease activity, and guide therapeutic strategies. Our primary aim is to identify novel biomarkers for PSC-IBD and conventional ulcerative colitis (UC) via proteomic approach. The secondary aim is to advance the etiopathogenic understanding of the diseases by linking specific proteomic profiles with disease phenotypes. This single-center, prospective, biomarker-discovery study will involve 50 participants with PSC-IBD, 50 with UC, and 50 healthy controls. Biopsy samples from five bowel segments will be analyzed for proteomic signatures by an untargeted approach. The findings will subsequently undergo multi-step external validation in separate cohorts of 30 patients with PSC-IBD and 30 with UC, utilizing targeted proteomics, immunohistochemistry, and ELISA in bowel mucosa and peripheral blood, respectively. This proposed study aims to identify novel biomarkers to improve the diagnostic accuracy of PSC-IBD and UC and refine the disease activity assessment. Its robust design and large sample size provide a strong foundation for successful biomarker identification, with the potential to enhance clinical management of patients.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
10700 - Other natural sciences
Result continuities
Project
—
Continuities
V - Vyzkumna aktivita podporovana z jinych verejnych zdroju
Others
Publication year
2026
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
PLOS ONE
ISSN
—
e-ISSN
1932-6203
Volume of the periodical
21
Issue of the periodical within the volume
1
Country of publishing house
US - UNITED STATES
Number of pages
10
Pages from-to
nestránkováno
UT code for WoS article
001677404200003
EID of the result in the Scopus database
2-s2.0-105028576021